Literature DB >> 27888285

Efficacy of statins for osteoporosis: a systematic review and meta-analysis.

T An1, J Hao2, S Sun1, R Li1, M Yang1, G Cheng3, M Zou4.   

Abstract

Our meta-analysis assessed the efficacy of statins on the risk of fracture, bone mineral density (BMD), and the markers of bone metabolism by collecting data from 33 clinical trials. We found that statin treatment was associated with bone metabolism. And statins seemed to be more effective on male patients with osteoporosis. The efficacy of statins for the treatment of osteoporosis has been controversial in previous studies and meta-analyses. Our meta-analysis was conducted to examine in detail the efficacy of statins on osteoporosis. We searched PubMed, Embase, and the Cochrane Library databases for clinical trials from inception to May 2016. We included studies that described the effect of statins on the risk of fracture, BMD, or bone turnover markers. Moreover, we also conducted subgroup analyses according to the skeleton site, patient gender, and length of follow-up. A total of 33 studies which included 23 observational studies (16 cohort studies and 7 case-control studies) and 10 randomized controlled trials (RCTs) were evaluated. These 33 studies included 314,473 patients in statin group and 1,349,192 patients in control group. Statins decreased the risk of overall fractures (OR = 0.81, 95% CI 0.73-0.89) and hip fractures (OR = 0.75, 95% CI 0.60-0.92). Furthermore, the use of statins was associated with increased BMD at the total hip (standardized mean difference (SMD) = 0.18, 95% CI 0.00-0.36) and lumbar spine (SMD = 0.20, 95% CI 0.07-0.32) and improved the bone formation marker, osteocalcin (OC) (SMD = 0.21, 95% CI 0.00-0.42). However, there was no positive effect on vertebral fractures, upper extremity fractures, BMD at the femoral neck, bone-specific alkaline phosphatase (BALP), and serum C-terminal peptide of type I collagen (S-CTX). Also, compared with male subgroups, the effect on female subgroups was only slightly positive or of no statistical significance. Our meta-analysis indicates that statin treatment may be associated with a decreased risk of overall fractures and hip fractures, an increased BMD at the total hip, BMD at the lumbar spine, and OC. Moreover, our results also show that statin treatment may have a greater effect on male patients than on female patients.

Entities:  

Keywords:  Bone maker; Bone mineral density; Fracture; HMG-CoA reductase inhibitors; Osteoporosis; Statins

Mesh:

Substances:

Year:  2016        PMID: 27888285     DOI: 10.1007/s00198-016-3844-8

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  61 in total

Review 1.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

2.  HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.

Authors:  Y S Chung; M D Lee; S K Lee; H M Kim; L A Fitzpatrick
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

3.  Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study.

Authors:  Julie A Pasco; Mark A Kotowicz; Margaret J Henry; Kerrie M Sanders; Geoffrey C Nicholson
Journal:  Arch Intern Med       Date:  2002-03-11

4.  A case of teriparatide-induced severe hypophosphatemia and hypercalcemia.

Authors:  Maiko Hajime; Yosuke Okada; Hiroko Mori; Yoshiya Tanaka
Journal:  J Bone Miner Metab       Date:  2014-02-20       Impact factor: 2.626

5.  Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women.

Authors:  Lars Rejnmark; Niels Henrik Buus; Peter Vestergaard; Lene Heickendorff; Frederik Andreasen; Mogens Lytken Larsen; Leif Mosekilde
Journal:  J Bone Miner Res       Date:  2004-02-16       Impact factor: 6.741

6.  Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia.

Authors:  Somlak Chuengsamarn; Suthee Rattanamongkoulgul; Somponge Suwanwalaikorn; Somkiat Wattanasirichaigoon; Larry Kaufman
Journal:  Bone       Date:  2010-01-04       Impact factor: 4.398

Review 7.  Osteoporosis and inflammation.

Authors:  Gregory R Mundy
Journal:  Nutr Rev       Date:  2007-12       Impact factor: 7.110

8.  Short-term effects of pitavastatin on biochemical markers of bone turnover in patients with hypercholesterolemia.

Authors:  Takafumi Majima; Akira Shimatsu; Yasato Komatsu; Noriko Satoh; Atsushi Fukao; Kiyoshi Ninomiya; Tadashi Matsumura; Kazuwa Nakao
Journal:  Intern Med       Date:  2007-12-17       Impact factor: 1.271

9.  Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2.

Authors:  Masanobu Tsubaki; Takao Satou; Tatsuki Itoh; Motohiro Imano; Masashi Yanae; Chisato Kato; Risa Takagoshi; Makiko Komai; Shozo Nishida
Journal:  Mol Cell Endocrinol       Date:  2012-05-10       Impact factor: 4.102

10.  The Role of RUNX2 in Osteosarcoma Oncogenesis.

Authors:  J W Martin; M Zielenska; G S Stein; A J van Wijnen; J A Squire
Journal:  Sarcoma       Date:  2010-12-09
View more
  35 in total

1.  Statin treatment and healthy adherer effects.

Authors:  T An; J Hao; S Sun; R Li; M Yang; G Cheng; M Zou
Journal:  Osteoporos Int       Date:  2017-05-29       Impact factor: 4.507

2.  Effects of drugs on bone metabolism in a cohort of individuals with traumatic spinal cord injury.

Authors:  Christina Kokorelis; Marlis Gonzalez-Fernandez; Marjorie Morgan; Cristina Sadowsky
Journal:  Spinal Cord Ser Cases       Date:  2019-01-16

3.  Increased risk of osteoporotic vertebral fracture in rheumatoid arthritis patients with new-onset cardiovascular diseases: a retrospective nationwide cohort study in Taiwan.

Authors:  W-J Hong; W Chen; K-J Yeo; P-H Huang; D-Y Chen; J-L Lan
Journal:  Osteoporos Int       Date:  2019-05-24       Impact factor: 4.507

Review 4.  27-Hydroxycholesterol, an endogenous selective estrogen receptor modulator.

Authors:  Sisi He; Erik R Nelson
Journal:  Maturitas       Date:  2017-07-31       Impact factor: 4.342

Review 5.  Statin therapy: does sex matter?

Authors:  Stephanie S Faubion; Ekta Kapoor; Ann M Moyer; Howard N Hodis; Virginia M Miller
Journal:  Menopause       Date:  2019-12       Impact factor: 2.953

Review 6.  Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics.

Authors:  Yajun Duan; Ke Gong; Suowen Xu; Feng Zhang; Xianshe Meng; Jihong Han
Journal:  Signal Transduct Target Ther       Date:  2022-08-02

7.  Comparative impact of systemic delivery of atorvastatin, simvastatin, and lovastatin on bone mineral density of the ovariectomized rats.

Authors:  Mostafa Shahrezaee; Ahmad Oryan; Farshid Bastami; Sepanta Hosseinpour; Mohammad Hossein Shahrezaee; Amir Kamali
Journal:  Endocrine       Date:  2018-01-25       Impact factor: 3.633

8.  Effects of hyperlipidemia on trabecular and cortical structures of the mandible.

Authors:  Dilara Nil Günaçar; Hatice Yemenoğlu; Gülbahar Ustaoğlu; Özkan Arıöz
Journal:  Dentomaxillofac Radiol       Date:  2021-07-20       Impact factor: 2.419

9.  Sex- and Gender-Based Pharmacological Response to Drugs.

Authors:  Franck Mauvais-Jarvis; Heiner K Berthold; Ilaria Campesi; Juan-Jesus Carrero; Santosh Dakal; Flavia Franconi; Ioanna Gouni-Berthold; Mark L Heiman; Alexandra Kautzky-Willer; Sabra L Klein; Anne Murphy; Vera Regitz-Zagrosek; Karen Reue; Joshua B Rubin
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

10.  The Effects of Fluvastatin on Indian Hedgehog Pathway in Endochondral Ossification.

Authors:  Munetada Ishikawa; Takenobu Ishii; Taiki Morikawa; Yuki Iijima; Kenji Sueishi
Journal:  Cartilage       Date:  2019-07-22       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.